UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November, 2025
Commission file number: 001-37891
AC IMMUNE SA
(Exact Name of Registrant as Specified in Its Charter)
EPFL Innovation Park
Building B
1015 Lausanne, Switzerland
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Report on Form 6-K (excluding Exhibit 99.3) shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File Nos. 333-227016, 333-249655 and 333-277940) and Form S-8 (File Nos. 333-213865, 333-216539 and 333-233019) of AC Immune SA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | |
| AC IMMUNE SA |
| |
| By: | /s/ Andrea Pfeifer |
| | Name: Andrea Pfeifer |
| | Title: Chief Executive Officer |
| | |
| | |
| By: | /s/ Christopher Roberts |
| | Name: Christopher Roberts |
| | Title: Chief Financial Officer |
| | |
Date: November 4, 2025 | | |
EXHIBIT INDEX
| | |
Exhibit
Number | | Description |
99.1 | | Interim Condensed Consolidated Financial Statements (Unaudited) (IFRS) as of and for the three and nine months ended September 30, 2025 |
99.2 | | Management’s Discussion and Analysis of Financial Condition and Results of Operations |
99.3 | | Press Release dated November 4, 2025 |
